Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1973 2
1974 1
1975 9
1976 11
1977 18
1978 14
1979 21
1980 8
1981 20
1982 21
1983 33
1984 23
1985 36
1986 37
1987 61
1988 39
1989 74
1990 103
1991 87
1992 125
1993 154
1994 152
1995 164
1996 210
1997 192
1998 197
1999 207
2000 215
2001 224
2002 235
2003 249
2004 243
2005 300
2006 283
2007 306
2008 316
2009 297
2010 372
2011 447
2012 472
2013 518
2014 580
2015 588
2016 574
2017 615
2018 616
2019 709
2020 714
2021 733
2022 705
2023 746
2024 274

Text availability

Article attribute

Article type

Publication date

Search Results

11,728 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Leukemia (both ALL and AML)"
Page 1
Acute Myeloid Leukemia: A Review.
Pelcovits A, Niroula R. Pelcovits A, et al. R I Med J (2013). 2020 Apr 1;103(3):38-40. R I Med J (2013). 2020. PMID: 32236160 Free article. Review.
Acute myeloid leukemia (AML) is a malignancy of the stem cell precursors of the myeloid lineage (red blood cells, platelets, and white blood cells other than B and T cells). ...Below we review the definitions, diagnosis and classification of AML and how this …
Acute myeloid leukemia (AML) is a malignancy of the stem cell precursors of the myeloid lineage (red blood cells, platelets, a …
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G. Garcia-Manero G. Am J Hematol. 2023 Aug;98(8):1307-1325. doi: 10.1002/ajh.26984. Epub 2023 Jun 8. Am J Hematol. 2023. PMID: 37288607 Review.
DISEASE OVERVIEW: The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males …
DISEASE OVERVIEW: The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood …
CPX-351 (vyxeos) in AML.
Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. Alfayez M, et al. Leuk Lymphoma. 2020 Feb;61(2):288-297. doi: 10.1080/10428194.2019.1660970. Epub 2019 Sep 24. Leuk Lymphoma. 2020. PMID: 31547736 Review.
For decades, the standard induction for patients with acute myeloid leukemia (AML) has been the combination of cytarabine with anthracycline (7 + 3 regimen). ...This is the first approved treatment specifically for patients with this subgroup of AML. The appr …
For decades, the standard induction for patients with acute myeloid leukemia (AML) has been the combination of cytarabine with …
Towards precision medicine for AML.
Döhner H, Wei AH, Löwenberg B. Döhner H, et al. Nat Rev Clin Oncol. 2021 Sep;18(9):577-590. doi: 10.1038/s41571-021-00509-w. Epub 2021 May 18. Nat Rev Clin Oncol. 2021. PMID: 34006997 Review.
With rapid advances in sequencing technologies, tremendous progress has been made in understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus revealing enormous genetic and clonal heterogeneity, and paving the way for precision medicine approa …
With rapid advances in sequencing technologies, tremendous progress has been made in understanding the molecular pathogenesis of acute myelo …
Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023.
Egan G, Tasian SK. Egan G, et al. Haematologica. 2023 Sep 1;108(9):2275-2288. doi: 10.3324/haematol.2022.281106. Haematologica. 2023. PMID: 36861399 Free PMC article. Review.
Although outcomes of children and adolescents with newly diagnosed acute myeloid leukemia (AML) have improved significantly over the past two decades, more than one-third of patients continue to relapse and experience suboptimal long-term outcomes. Given the small n …
Although outcomes of children and adolescents with newly diagnosed acute myeloid leukemia (AML) have improved significantly ov …
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. Schuurhuis GJ, et al. Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Blood. 2018. PMID: 29330221 Free PMC article. Review.
Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-esta …
Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acut …
Targeting the undruggable: menin inhibitors ante portas.
Dempke WCM, Desole M, Chiusolo P, Sica S, Schmidt-Hieber M. Dempke WCM, et al. J Cancer Res Clin Oncol. 2023 Sep;149(11):9451-9459. doi: 10.1007/s00432-023-04752-9. Epub 2023 Apr 27. J Cancer Res Clin Oncol. 2023. PMID: 37103568 Review.
In the revumenib phase I/II AUGMENT-101 trial (N = 68) with very heavily pretreated AML patients the ORR was 53% with a CR rate of 20%. ...Similar results have been reported for ziftomenib in the phase I/II COMET-001 trial. ORR was 40% and CRc was 35% in A …
In the revumenib phase I/II AUGMENT-101 trial (N = 68) with very heavily pretreated AML patients the ORR was 53% with a CR rat …
Immunotherapy in leukaemia.
Mu X, Chen C, Dong L, Kang Z, Sun Z, Chen X, Zheng J, Zhang Y. Mu X, et al. Acta Biochim Biophys Sin (Shanghai). 2023 Jun 2;55(6):974-987. doi: 10.3724/abbs.2023101. Acta Biochim Biophys Sin (Shanghai). 2023. PMID: 37272727 Free PMC article. Review.
Remarkable progress has been made in basic research and preclinical studies for acute leukaemia compared to that of the many other types/subtypes of leukaemia, especially the exploration of the biological basis and application of immunotherapy in acute myeloid le …
Remarkable progress has been made in basic research and preclinical studies for acute leukaemia compared to that of the many other ty …
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia.
Ivanov V, Yeh SP, Mayer J, Saini L, Unal A, Boyiadzis M, Hoffman DM, Kang K, Addo SN, Mendes WL, Fathi AT. Ivanov V, et al. Future Oncol. 2022 Aug;18(26):2879-2889. doi: 10.2217/fon-2022-0450. Epub 2022 Jul 19. Future Oncol. 2022. PMID: 35852098 Free article. Review.
Prevention of relapse is a major therapeutic challenge and an unmet need for patients with acute myeloid leukemia (AML). Venetoclax is a highly selective, potent, oral BCL-2 inhibitor that induces apoptosis in AML cells. When combined with azacitidine, it lea …
Prevention of relapse is a major therapeutic challenge and an unmet need for patients with acute myeloid leukemia (AML). Venet …
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, Hasenkamp J, Kiehl M, Koldehoff M, Krause SW, Lehners N, von Lilienfeld-Toal M, Löhnert AY, Maschmeyer G, Teschner D, Ullmann AJ, Penack O, Ruhnke M, Mayer K, Ostermann H, Wolf HH, Cornely OA. Mellinghoff SC, et al. Ann Hematol. 2018 Feb;97(2):197-207. doi: 10.1007/s00277-017-3196-2. Epub 2017 Dec 7. Ann Hematol. 2018. PMID: 29218389 Free PMC article. Review.
Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies undergoing remission-induction chemotherapy for acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) and recipients of al …
Immunocompromised patients are at high risk of invasive fungal infections (IFI), in particular those with haematological malignancies underg …
11,728 results
You have reached the last available page of results. Please see the User Guide for more information.